Sort publications on year
-
Pharmaco-Economics
What is the budget impact of a new treatment or new health technology arriving on the market?
DERVAUX B, LE FUR C, DUBOIS S, JOSSERAN A, DETOURNAY B; participants of round table No. 3 of Giens XXXIII
Therapie ; 2017;72(1):93-103
-
Pharmaco-Economics
Quel impact budgĂ©taire pour lâarrivĂ©e dâun nouveau traitement ou dâune nouvelle technologie de santé ?
DERVAUX B, LE FUR C, DUBOIS S, JOSSERAN A, DETOURNAY B; les participants Ă la table ronde n(o)Â 3 de Giens XXXIII.
Therapie ; 2017;72(1):81-91
-
Biometry and database analysis
Two year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database.
AGOSTINI A, GODARD C, LAURENDEAU C, BENMAHMOUD ZOUBIR A, LAFUMA A, LĂVY-BACHELOT L, GOURMELEN J, LINET T.
Eur J Contracept Reprod Health Care ; 2018;23(6):421-426
-
Market Access
Clinical added value of drugs : An empirical survey of French transparency committee opinions.
DETOURNAY B, BOREL T, TRANCART M, EMERY C, COUDRAY-OMNES C, LEEM WORKING GROUP ONHEALTH TECHNOLOGY ASSESSMENT OF DRUGS.
Thérapie ; 2018;S0040-5957(18)30245-2
-
Pharmaco - Epidemiology
Palivizumab immunoprophylaxis: use in clinical practice, safety and beneficial effects in France.
PINQUIER D, GOUYON JB, FAUROUX B, MONS F, VICAUT E, BENDJENANA H, ROUFFIAC E, MARRET S, AUJARD Y.
Arch Pediatr. ; 16(11):1443-1452
-
Public Health and Epidemiology
Management of innovative medicines in hospitals: an international comparison
LAFUMA A, TILLEUL P
EJHPP Practice ; 12(1):26-27
-
Public Health and Epidemiology
La nécessaire clarification de la place des réseaux de santé
SANNINO N, DONIO V
FiliÚres & Réseaux 2 Santé ; (7):44-45
-
Public Health and Epidemiology
Methodological issues in determining the dimensionality of composite health measures using principal component analysis: Case illustration and suggestions for practice
COSTE J, BOUĂE S, ECOSSE E, LEPLĂGE A, POUCHOT J
Quality of life Research ; 14:641-654
-
Public Health and Epidemiology
Et si la France n’Ă©tait plus qu’un comptoir de distribution de mĂ©dicaments?
FAGNANI F, SAINT-CAST F, GADENNE S, HERTZ JL, AMEYE V
Annales des Mines ; 31-35
-
Others
Care pathway, towards the establishment of tailored funding: Reasons and criteria for success.
EMERY G, LE FUR C, EPIS-DE-FLEURIAN AA, JOSSERAN A; Participants of Giens Round Table ‘Medico-economy’ of Giens XXXIII.
Therapie ; 2018;73(1):33-40
-
Pharmaco - Epidemiology
Health related quality of life in patients with community-acquired pneumococcal pneumonia in France.
ANDRADE LF, SABA G, RICARD JD, MESSIKA J, GAILLAT J, BONNIN P, CHIDIAC C, ILLES HG, LAURICHESSE H, DETOURNAY B, PETITPRETZ P, DE POUVOURVILLE G.
Health Qual Life Outcomes ; 2018;16 (1):28
-
Pharmaco - Epidemiology
L’Ă©valuation risque/bĂ©nĂ©fice dans les domaines de la santĂ© et de l’environnement : similitudes et diffĂ©rences
FAGNANI F
Environnement Risques & Santé ; 1(3):1-3
-
Pharmaco - Epidemiology
Indices de satisfaction des patients atteints d’une dystrophie musculaire de Duchenne de Boulogne et ventilĂ©s Ă domicile
RAPHAEL JC, DAZORD A, JAILLARD P, ANDRONIKOF-SANGLADE A, BENONY H, KOVESS V, CHARPAK Y, AURIANT I
La Revue Neurologique ; 4 (158) : 453-460
-
Public Health and Epidemiology
Avulsions dentaires et kystectomies chez les patients prĂ©sentant un dĂ©ficit constitutionnel enfacteurs de l’hĂ©mostase : conduite Ă tenir
ALANTAR A, GINISTY D, HASSIN M, LAFUMA A, PRINC G, STIELTJES N
Médecine Buccale Chirurgie Buccale ; 11(3):121-143
-
Public Health and Epidemiology
Evolution du traitement de l’arthrose en mĂ©decine gĂ©nĂ©rale aprĂšs la mise sur le marchĂ© des AINS anti-cox 2 sĂ©lectifs et co-prescriptions de gastro-protecteurs
BOUEE S, CHARLEMAGNE A, FAGNANI F, SPIRA R, LE JEUNNE P, SERMET C, NAUDIN F, LANCRY PJ
Revue du Rhumatisme ; 71(5):378-385